Orbis BioCapital Limited reported 499,926 Class A ordinary shares, equal to 9.98% of Universe Pharmaceuticals INC. The passive designation matters because the certification says the securities were not acquired or held to change or influence control, except for nomination-related activities.
Key Highlights
- Orbis BioCapital Limited used a Schedule 13G under Rule 13d-1(c) to report the position.
- Chunhua Zheng is identified as Orbis BioCapital Limited’s sole owner and controller.
- Orbis BioCapital Limited and Chunhua Zheng agreed to a joint filing signed September 1, 2026.
Universe Pharmaceuticals INC (NASDAQ: UPC) is the subject of a 9.98% ownership report from Orbis BioCapital Limited. The position covers 499,926 Class A ordinary shares.
Orbis BioCapital Limited submitted the position through a Schedule 13G under Rule 13d-1(c), with the securities identified as Class A ordinary shares. Orbis is a limited-liability company formed in the British Virgin Islands. The reported holding is attributed to both Orbis and Zheng at 499,926 shares and 9.98%. Universe Pharmaceuticals is described as a Cayman Islands exempted company, while Zheng’s listed domicile is the People’s Republic of China.
Ownership Certification Addresses Control Purpose
The ownership certification states that the securities were not acquired or held to change or influence control of Universe Pharmaceuticals. It also says they were not acquired or held in connection with a transaction having that purpose or effect. The certification preserves an exception for activities solely connected with a nomination under Section 240.14a-11. Orbis and Zheng agreed to submit the ownership statement jointly under Rule 13d-1(k), with Zheng signing as Orbis’ director on September 1, 2026.
FAQs
Q: Who reported a 9.98% stake in Universe Pharmaceuticals INC?
A: Orbis BioCapital Limited reported the position through a Schedule 13G. The reported holding consists of 499,926 Class A ordinary shares.
Q: What does the ownership certification say about control of Universe Pharmaceuticals INC?
A: The certification says the securities were not acquired or held to change or influence control of Universe Pharmaceuticals INC. It identifies a nomination-related exception.
Q: How is the 9.98% Universe Pharmaceuticals stake calculated?
A: The filing calculates 9.98% using 499,926 shares against 5,008,313 Class A ordinary shares outstanding as of July 27, 2026. Orbis and Chunhua Zheng are each listed with 499,926 shares because Zheng wholly owns and controls Orbis.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.